BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25378357)

  • 1. Exploring the link between industry payments to doctors and prescribing habits.
    Carlat D
    BMJ; 2014 Nov; 349():g6651. PubMed ID: 25378357
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharma corruption.
    Prescrire Int; 2014 Apr; 23(148):88. PubMed ID: 24860888
    [No Abstract]   [Full Text] [Related]  

  • 3. Doctors and the drug industry: reader feedback.
    Warrier R; Houghton B
    Am J Med; 2005 Oct; 118(10):1175-6; author reply 1176. PubMed ID: 16194656
    [No Abstract]   [Full Text] [Related]  

  • 4. The details are in the field.
    Schwab AP
    Am J Bioeth; 2010 Jan; 10(1):19-21. PubMed ID: 20077330
    [No Abstract]   [Full Text] [Related]  

  • 5. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement.
    Moynihan R
    BMJ; 2003 May; 326(7400):1189-92. PubMed ID: 12775621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Banning pens and pads misses the main point.
    Terry SF; Burke W
    Am J Bioeth; 2003; 3(3):63-5. PubMed ID: 14594500
    [No Abstract]   [Full Text] [Related]  

  • 7. The devil in the detail(ing).
    Morreim H
    Am J Bioeth; 2010 Jan; 10(1):15-7. PubMed ID: 20077328
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug detailers, professionalism, and prudence.
    Brody H
    Am J Bioeth; 2010 Jan; 10(1):9-10. PubMed ID: 20077325
    [No Abstract]   [Full Text] [Related]  

  • 9. Avoiding over-deterrence in managing physicians' relationships with industry.
    Stell LK
    Am J Bioeth; 2010 Jan; 10(1):27-9. PubMed ID: 20077334
    [No Abstract]   [Full Text] [Related]  

  • 10. Huddle gets it right, most docs don't.
    Rubin PH
    Am J Bioeth; 2010 Jan; 10(1):17-9. PubMed ID: 20077329
    [No Abstract]   [Full Text] [Related]  

  • 11. Contact with pharmaceutical representatives: where does prudence lead?
    Appelbaum PS
    Am J Bioeth; 2010 Jan; 10(1):11-3. PubMed ID: 20077326
    [No Abstract]   [Full Text] [Related]  

  • 12. Why academic medical centers should ban drug company gifts to individuals.
    Strong C
    Am J Bioeth; 2010 Jan; 10(1):13-5. PubMed ID: 20077327
    [No Abstract]   [Full Text] [Related]  

  • 13. Sunshine Act update.
    W V Med J; 2013; 109(5):40. PubMed ID: 24294711
    [No Abstract]   [Full Text] [Related]  

  • 14. Public disclosure of conflicts of interest: moving the policy debate forward.
    Campbell EG
    Arch Intern Med; 2010 Apr; 170(8):667. PubMed ID: 20421548
    [No Abstract]   [Full Text] [Related]  

  • 15. Why self-regulation does not work: resolving prescription corruption caused by excessive gift-giving by pharmaceutical manufacturers.
    Mehta RS
    Food Drug Law J; 2008; 63(4):799-821. PubMed ID: 19593922
    [No Abstract]   [Full Text] [Related]  

  • 16. Doctors and the drug industry: reader feedback.
    Nardone DA
    Am J Med; 2005 Oct; 118(10):1176-7; author reply 1177. PubMed ID: 16194658
    [No Abstract]   [Full Text] [Related]  

  • 17. The pitfalls of misreading: what does "industry funding of medical education" actually say?
    Spielman B
    Am J Bioeth; 2010 Jan; 10(1):24-5. PubMed ID: 20077332
    [No Abstract]   [Full Text] [Related]  

  • 18. The AAMC exhibits the behavior it condemns.
    Stossel TP
    Am J Bioeth; 2010 Jan; 10(1):26-7. PubMed ID: 20077333
    [No Abstract]   [Full Text] [Related]  

  • 19. Radiology and industry: can this relationship be saved?
    Forman HP
    J Am Coll Radiol; 2006 May; 3(5):333-4. PubMed ID: 17412076
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to open peer commentaries on "The pitfalls of deducing ethics from economics: why the Association of American Medical Colleges is wrong about pharmaceutical detailing".
    Huddle TS
    Am J Bioeth; 2010 Jan; 10(1):W1-3. PubMed ID: 20077322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.